Ablynx: Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings (the "Transparency Law")

REGULATED INFORMATION

(firmenpresse) - GHENT, BELGIUM -- (Marketwired) -- 04/17/13 -- today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from KBC Asset Management NV.

KBC Asset Management NV notified that they have exceeded the 3% threshold and now hold 1,472,009 Ablynx shares, which represent 3.03% of the current 48,505,516 outstanding shares of Ablynx.

Full versions of all transparency notifications are available on the website of Ablynx, under the section .

is a biopharmaceutical company engaged in the discovery and development of , a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately and five Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium.
More information can be found on .

press release in pdf:



Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193
+32 (0)473 39 50 68
e:

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:
Follow us on Twitter (at)AblynxABLX

Mary-Jane Elliott
Amber Bielecka
Claire Dickinson
t: +44 207 920 2330
e:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 17.04.2013 - 16:29 Uhr
Sprache: Deutsch
News-ID 250067
Anzahl Zeichen: 0

contact information:
Town:

GHENT, BELGIUM

Kategorie:

Healthcare

Diese Pressemitteilung wurde bisher 267 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Ablynx: Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings (the "Transparency Law")"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regar ...

GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx